H. Graaf

发表

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

C. Seynaeve, S. Linn, V. Tjan-Heijnen, 2017 .

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer

E. Vries, A. Bos, H. Piersma, 2000, British Journal of Cancer.

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines

J. Schellens, J. Beijnen, L. M. Henricks, 2016, Cancer Chemotherapy and Pharmacology.

A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer

W. M. Smit, G. Creemers, P. Willemse, 2007 .

Dose intensity of standard adjuvant cmf with G-CSF for premenopausal node-positive breast cancer patients.

E. Vries, H. Piersma, P. Willemse, 1998 .

Cytological scoring system in primary breast cancer

W. Sluiter, G. McKee, I. Robinson, 1995, Cytopathology : official journal of the British Society for Clinical Cytology.

Evaluation of a cytological scoring system for predicting histological grade and disease‐free survival in primary breast cancer

W. Sluiter, P. Willemse, H. Bergen, 1994, Cytopathology : official journal of the British Society for Clinical Cytology.

Expected survival with and without second‐line palliative chemotherapy: who wants to know?

Linda J. M. Oostendorp, P. Stalmeier, P. Ottevanger, 2015, Health expectations : an international journal of public participation in health care and health policy.

Abstract P1-15-20: DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013-04)

H. Putter, M. Welters, J. Nortier, 2019, Poster Session Abstracts.

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Breast.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

W. M. Smit, H. Hollema, P. Willemse, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A. Wymenga, H. Tinteren, M. Hamaker, 2014, Breast.

J. Nortier, M. Los, A. Wymenga, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.